Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)

British Journal of Cancer

Volumn 90, Issue 1, 2004, Pages 82-86

  Cappuzzo, F ^a   Bartolini, S ^a   Ceresoli, G L ^b   Tamberi, S ^c   Spreafico, A ^b   Lombardo, L ^b   Gregorc, V ^b   Toschi, L ^a   Calandri, C ^a   Villa, E ^b   Crino L ^a  

^a BELLARIA HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Hospital of Faenza   (Italy)

Author keywords

Non small cell lung cancer; Thyrosine kinase inhibitor elderly

Indexed keywords

GEFITINIB;

ACNE; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN TOXICITY;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUINAZOLINES; SKIN DISEASES;

EID: 10744220834     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601470     Document Type: Article

References (24)

1. Argiris A, Mittal N, Masters G (2003) Gefitinib (ZD1839) as first line, compassionate use therapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22: A2729
2. Balducci L, Hardy CL, Lyman GH (2000) Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7: 539-547
3. Common toxicity criteria: National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment (1993). Bethesda
4. Copin M, Kommareddy A, Behnken D, McLeod H, Trinkaus K, Ali A, Read W, Govindan R (2003) Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22: A3048
5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
7. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353
8. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51: 15-36
9. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95: 362-372
10. Hanna NH, Shepherd FA, Rosell R, Pereira JR, De Marinis F, Fossella F, Kayitalire L, Paul S, Einhorn LH, Bunn PA (2003) A phase III study of pemetrexed versus docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 22: A2503
11. Huang SM, Harari PM (1999) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17: 259-269
12. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067
13. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139
14. Janne PA, Ostler PA, Lucca J, Fidias P, Skarin AT, Lynch TJ, Johnson BE, Farber D (2002) ZD1839 ('Iressa') shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol. Proc Am Soc Clin Oncol 21: A1274
15. Kommareddy A, Coplin M, Behnken D, Romvari E, Trinkaus K, Read W, Govindan RT (2003) Gefitinib as a first line therapy for patients with advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22: A2834
16. Kris MG, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, Feyereislova A, Ochs J, Averbuch S (2000) Objective regression in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29(Suppl 1): 72 (abstract 233)
17. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albani KS, Brahmer JR, Sandier A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A (2002) A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a
18. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer, implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173-181
19. Pallis AG, Mavroudis D, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis IG, Georgoulias V (2003) V ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 40: 301-307
20. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Lima CR, Ettienne K, Vaughn J, Bepler G, Lee Moffitt H (2002) ZD1839 ('Iressa') as a single agent for the treatment of metastatic non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: A1269
21. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385
22. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232
23. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103
24. Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216